Short Interest in Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Expands By 20.9%

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) was the target of a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 223,283 shares, a growth of 20.9% from the December 15th total of 184,642 shares. Based on an average daily volume of 230,112 shares, the days-to-cover ratio is presently 1.0 days. Approximately 3.8% of the shares of the company are short sold. Approximately 3.8% of the shares of the company are short sold. Based on an average daily volume of 230,112 shares, the days-to-cover ratio is presently 1.0 days.

Analyst Ratings Changes

SLRX has been the topic of several analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Salarius Pharmaceuticals in a research report on Monday, December 29th. Wall Street Zen lowered shares of Salarius Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, January 3rd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Salarius Pharmaceuticals presently has an average rating of “Sell”.

Salarius Pharmaceuticals Price Performance

SLRX stock opened at $0.84 on Wednesday. The firm has a market cap of $4.89 million, a PE ratio of -0.02 and a beta of 0.33. The firm has a 50 day simple moving average of $0.81 and a 200 day simple moving average of $4.41. Salarius Pharmaceuticals has a 12 month low of $0.51 and a 12 month high of $108.00.

Salarius Pharmaceuticals (NASDAQ:SLRX) last announced its earnings results on Friday, November 14th. The company reported ($1.81) EPS for the quarter, beating the consensus estimate of ($33.60) by $31.79.

Salarius Pharmaceuticals Company Profile

Salarius Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that target epigenetic and post‐translational modification pathways in cancer. The company’s lead candidate, seclidemstat (SP‐2577), is designed to inhibit lysine‐specific demethylase 1 (LSD1) and modulate the tumor microenvironment, with a primary focus on treating Ewing sarcoma, a rare and aggressive bone and soft tissue cancer affecting children and young adults.